CHMP Recommends EU Approval of Roche's Susvimo, the First Continuous Delivery Treatment for Neovascular Age-related Macular Degeneration
July 25, 2026
July 25, 2026
BASEL, Switzerland, July 25 -- Roche, a biotech company, issued the following news release on July 24, 2026:
* * *
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
* Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD
* Positive recommendation is based on data from the . . .
* * *
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
* Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD
* Positive recommendation is based on data from the . . .